This study included one hundred consecutive newly diagnosed obese patients (BMI ≥ 95th percentile) 14–18 years old with NAFLD (ultrasound proven) and persistently elevated alanine aminotransferase (ALT) levels greater than 60 U/L for 1–6 months; these patients composed the patient group (Group I). This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.